Alithea Genomics Revolutionizes RNA Sequencing with CHF 2.8 Million Seed Financing Extension

Alithea Genomics, a game-changer in RNA sequencing, secures CHF 2.8 million in seed financing extension led by Novalis Biotech. Their innovative BRB-seq and DRUG-seq technologies streamline RNA sample preparation, slashing costs and time. Big pharma giants now rely on Alithea's solutions for drug development. The company's expansion to Lausanne, Switzerland, signals a new era of growth. CEO Riccardo Dainese credits Venture Leaders and Venture Kick for propelling Alithea's evolution from a small spin-off to a thriving life science powerhouse. Alithea's mission to simplify "big RNA data" generation is on track with this funding boost.